Doctolib account plan
Healthcare technology solutions
At a glance
Doctolib is a European health software company serving 520,000 health professionals and 90 million patients, with €422 million of recurring revenue in 2025.
Doctolib, founded in 2013 in France, started with online appointment booking and now sells practice software, patient records, teleconsultation, messaging, billing and AI assistants to health professionals, while patients use it for free. It claims 520,000 health professionals and 90 million patients across five European countries: France, Germany, Italy, the Netherlands and the United Kingdom. Recurring revenue (ARR) was €348 million in 2024 and €422 million in 2025, the company became profitable in autumn 2025, and it has about 3,000 employees. It is privately held, valued at an implied €3.6 billion after a spring 2026 secondary sale; Nvidia took a minority stake in October 2026. Co-founder Stanislas Niox-Chateau is CEO.
Strategic priorities
- AI across the product
- "AI is central to our roadmap. We want to embed AI in every part of the product." Doctolib is building assistants for clinicians (Consultation Assistant, Virtual Phone Assistant) and a health companion for patients, funded in part by the Nvidia investment.
- From booking to full practice software
- Evolve from an appointment tool to a full-service ecosystem: a clinical and financial management system for documentation and billing, smart check-in, Siilo messaging and interoperability with national EHRs.
- European expansion
- Expand into new European markets beyond France and Germany; the UK became the fifth market in 2026 through the Medicus acquisition.
- Headcount growth
- Niox-Chateau plans to double the workforce from 2,800 people in four to five years, and the Nvidia money is to accelerate hiring.
- Data privacy and European hosting
- Health data stays hosted in Europe, models are adapted from open models, and the company says it does not and will not sell patient data.
Latest results
Recurring revenue (ARR) rose to €422 million in 2025 from €348 million in 2024, when it grew 22.5% and EBITDA was a loss of €53.8 million. In October 2025 the CEO announced that Doctolib had become profitable. In spring 2026 about €300 million of existing shares changed hands at an implied €3.6 billion valuation, below the €5.8 billion of 2022; this did not fund the company. No guidance is published.
Investments and deals
- Medicus Health acquisition (UK)
- Acquired London GP practice management software Medicus Health in May 2026, terms undisclosed, with a commitment to invest "more than £100 million sterling" in the UK, hire 150 people and open a primary-care R&D centre.
- Nvidia minority stake
- Nvidia took a minority stake on 13 October 2026, with no board seat, to accelerate hiring and the development of Doctolib's models and AI assistants.
- Patient health companion
- Launched a patient assistant in October 2025, first for parents of children under 4.
Challenges and risks
- Larger software competitors
- Competes with Cegedim and CompuGroup Medical in France and the Optum-TPP near-duopoly in UK GP software; the CEO calls Doctolib three times smaller than its European competitors.
- Competition authority fine
- Fined €4.665 million by the Autorité de la concurrence in November 2025 for exclusivity practices, tied sales and the MonDocteur acquisition; the appeal is pending.
- Lower valuation
- The spring 2026 secondary sale implied €3.6 billion, about 38% below the €5.8 billion valuation of March 2022.
- Country-by-country complexity
- Financing regimes, reimbursement rules and patient journeys differ across France, Germany and Italy, so team and brand must be rebuilt in each country.
- Sovereignty and AI trust
- Computing power from a US partner raises a sovereignty question, and the new AI tools must still prove their usefulness in documentation, administration and clinical decision support.
What leadership says
“We have 2,800 people today. We will double that population [in] four [to] five years.”
“If you want to change the world, you need to build systemic technology, not just a layer on top.”
“Doctolib has been profitable for a few weeks”
“AI is central to our roadmap. We want to embed AI in every part of the product.”
Where a supplier can help
- Recruiting and onboarding at scale
- Tied to the headcount growth priority and the 150 UK hires: recruiting, onboarding and HR tooling for a workforce set to double.
- AI infrastructure in Europe
- Tied to the AI priority and the European hosting commitment: compute, model evaluation and privacy tooling that keep health data in Europe.
- Localisation for new markets
- Tied to European expansion and country-by-country complexity: reimbursement, billing and EHR interoperability expertise for the UK and future markets.
- Compliance and competition-law support
- Tied to the competition authority fine: commercial compliance and contract governance for sales practices.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Doctolib?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Nvidia invests in Doctolib: a look back at a French success story (Frenchweb)
- Nvidia is taking a minority stake in Doctolib, announced by Jensen Huang in Paris on 13 October 2026; no governance rights and no board seat, commercial terms not published.
- Doctolib claims 520,000 health professionals and 90 million patients across five European countries; practitioners pay a subscription, patients book for free.
- The offer has grown from the online agenda into practice software, patient records, teleconsultation, messaging and document exchange, and now AI assistants for clinicians plus a health companion for patients.
- Recurring revenue (ARR) was €348 million in 2024 and €422 million in 2025; the CEO said on BFM TV in autumn 2025 the company was "profitable for a few weeks" (translated).
- Spring 2026: about €300 million of existing shares changed hands at an implied €3.6 billion valuation, about 38% below the €5.8 billion of the March 2022 €500 million round; Generation Investment Management, A.P. Møller Holding and Athos KG entered. This was not new money for the company.
- The Nvidia money is to accelerate hiring and the development of its models and AI assistants; models are adapted from open models and health data stays hosted in Europe.
- Competes with medical software publishers Cegedim and CompuGroup Medical; fined €4.665 million by the Autorité de la concurrence in November 2025 (appeal pending).
- Doctolib founder returns to HEC with ambition and the fragile architecture of AI health
- Interview and HEC Talks session (15 September 2025): Niox-Chateau's north star is "user, user, user" — practitioners and patients — with the business model following impact.
- Headcount: "We have 2,800 people today. We will double that population [in] four [to] five years."
- On profitability: "This year might be the first one in which we are not in the red"; he declined to discuss timing, including IPO talk.
- AI: healthcare is at "day one" of an AI revolution in clinical decision-making, with "zero compromise on data privacy [and] security"; AI is to automate notes so clinicians look at patients, not screens.
- Operating in France, Germany and Italy: financing regimes, reimbursement rules and patient journeys differ; modular technology travels, team and brand must be rebuilt per country.
- Opposed mandatory bank-card imprinting for the proposed €5 no-show penalty ("taxe lapin"), preferring a solution carried by Assurance Maladie.
- How letting go of one dream sparked a healthcare revolution (HEC Talks)
- Doctolib's mission, launched in 2013 with limited capital: "improve the daily lives of healthcare providers and make access to care faster and simpler for everyone."
- Scale cited: unicorn since March 2019 (valued above €1 billion), serving 50 million people and over 400,000 practitioners.
- AI "will be a revolution for health professional"; "We are at day one of our journey"; the goal is "not to replace health professional" but to automate administrative, financial and repetitive tasks.
- Rationale for patient-facing AI: 10% of Google searches and 15% of ChatGPT queries are about medical knowledge; Doctolib is building AI around "verified medical knowledge" and "medical accuracy".
- Leadership method: 80% of his early time in the field, door-to-door with practitioners, even working as a medical assistant; become "super expert on content".
- Advice: "If you want to change the world, you need to build systemic technology, not just a layer on top."
- How this platform mastered the art of appointment management (ICT&health)
- 450,000 healthcare professionals and 80 million patients use Doctolib; 25 million users in Germany alone.
- Revenue model: practitioners pay a monthly subscription for a resource management system; patients never pay; "we do not and will not sell patient data."
- Product roadmap: a clinical and financial management system for documentation and billing, smart check-in, Siilo secure messaging, interoperability with national EHRs (DMP in France, EPA in Germany).
- "AI is central to our roadmap": the Virtual Phone Assistant saves practices up to 45 hours a week; the Consultation Assistant (speech-to-text) is live in France and launching in Germany.
- No-show rates brought down to around 2%, below 1% at some institutions, via waitlists and reminders.
- Next: from appointment tool to a full-service ecosystem across the patient journey, and expansion into new European markets beyond France and Germany.
- Twelve years after its creation, Doctolib is finally profitable (Maddyness, from BFM TV)
- On BFM TV Niox-Chateau announced: "Doctolib has been profitable for a few weeks" (translated).
- 2024: €348 million of annual recurring revenue, up 22.5%; EBITDA was a €53.8 million loss, €33.3 million less than in 2023.
- About 3,000 employees; claims 400,000 caregivers and 80 million patients in Europe, 50 million in France.
- "Being profitable lets us be masters of our own destiny" (translated).
- Launching a patient assistant, first for parents of children under 4; "We need to build even more AI agents to help caregivers and patients" and "The AI battle is now" (translated).
- Positions Doctolib as "three times smaller than our European competitors and fifteen times smaller than our American competitors" (translated).
- Doctolib acquires its British competitor Medicus and enters the UK market (Maddyness UK)
- Doctolib acquired London startup Medicus Health, GP practice management software validated by NHS England in June 2025; terms undisclosed.
- The UK is Doctolib's fifth market after France, Germany, Italy and the Netherlands.
- Commitment: "more than £100 million sterling" invested in the UK, "hiring 150 people" and an R&D centre for primary care innovation (Niox-Chateau).
- Medicus's 25-person workforce "will double this year alone"; founder Emile Axelrad heads Doctolib UK and becomes a significant Doctolib shareholder.
- Target: the UK GP software market held by the near-duopoly of Optum (UnitedHealth) and TPP; in France Doctolib challenges Cegedim and Compugroup Medical.
- Doctolib: 3,000 employees, €422 million of revenues last year, profitable for a few months, valued at €3.6 billion after a recent secondary transaction (vs €5.8 billion in 2022).
Questions about Doctolib
What does Doctolib do?
Doctolib sells subscription software to health professionals: online booking, practice management, patient records, teleconsultation, messaging, billing and AI assistants. Patients use it for free.
What is Doctolib's revenue?
Recurring revenue (ARR) was €422 million in 2025, up from €348 million in 2024; the company became profitable in autumn 2025.
How many employees does Doctolib have?
About 3,000 employees, and the CEO plans to double the workforce within four to five years.
Who leads Doctolib?
Co-founder Stanislas Niox-Chateau is CEO; Jessy Bernal and Ivan Schneider are the other co-founders.
In which countries does Doctolib operate?
France, Germany, Italy, the Netherlands and, since the 2026 Medicus acquisition, the United Kingdom.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)